28.12.2016 05:06:42
|
FTC Puts Conditions On Abbott' Proposed $25 Bln Acquisition Of St. Jude Medical
(RTTNews) - The U.S. Federal Trade Commission put conditions on Abbott Laboratories' (ABT) proposed $25 billion acquisition of rival medical device maker St. Jude Medical Inc. (STJ).
Abbott Laboratories has agreed to divest two medical device businesses to settle FTC charges that its proposed acquisition of St. Jude Medical Inc. would likely be anticompetitive.
The FTC's complaint alleges that without a remedy, the proposed acquisition would harm competition in the U.S. markets for vascular closure devices, which are used to close holes in arteries from the insertion of catheters, and for "steerable" sheaths, which are used to guide catheters for treating heart arrhythmias.
The proposed consent order requires the parties to divest to Tokyo-based medical device maker Terumo Corporation all rights and assets related to St. Jude's vascular closure device business and Abbott's steerable sheath business. Terumo does not currently sell any vascular closure devices or steerable sheaths but has sold related products and medical devices in the U.S. market for more than 30 years, and possesses the industry experience and reputation necessary to replace competition, according to the FTC. The order requires both companies to assist Terumo with establishing its manufacturing capabilities.
Under the proposed order, Abbott is also required to notify the FTC if it intends to acquire lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics, known as ACT. Lesion-assessing ablation catheters provide feedback to physicians regarding the force being applied by the catheter or the temperature of the ablation target.
Currently, only St. Jude and one other company provide lesion-assessing ablation catheters in the United States. Abbott and ACT have formed a partnership to develop these catheters. After the acquisition of St. Jude, if Abbott acquired lesion-assessing ablation catheter assets from ACT, it could eliminate additional competition that would result from an independent ACT.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!